Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 27, 2015 11:35 PM ET

Biotechnology

Company Overview of KaloBios Pharmaceuticals, Inc.

Company Overview

KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, develops monoclonal antibody therapeutics for the treatment of cancer in the United States. The company’s product candidates include KB004, which is in a Phase II clinical trial for the treatment of myelodysplastic syndrome and myelofibrosis; and KB003 that completed Phase II clinical trial to treat chronic myelomonocytic leukemia, an orphan oncology indication. KaloBios Pharmaceuticals, Inc. was founded in 2000 and is headquartered in South San Francisco, California.

442 Littlefield Avenue

South San Francisco, CA 94080

United States

Founded in 2000

32 Employees

Phone:

650-243-3100

Key Executives for KaloBios Pharmaceuticals, Inc.

Interim Chief Executive Officer, Interim President and Chief Financial Officer
Age: 43
Total Annual Compensation: $340.0K
Chief Scientific Officer
Age: 63
Total Annual Compensation: $287.5K
Compensation as of Fiscal Year 2014.

KaloBios Pharmaceuticals, Inc. Key Developments

KaloBios Pharmaceuticals, Inc. Appoints Ronald A. Martell to the Position of Executive Chairman

KaloBios Pharmaceuticals, Inc. announced the appointment of Ronald A. Martell, to the position of Executive Chairman. Mr. Martell currently serves as a member of the KaloBios Board of Directors. In this new role, he will work directly with the company's senior management team to refine and execute on the strategic plan to transition KaloBios to a focused monoclonal antibody company developing therapeutics for orphan oncology indications with high unmet medical need. Mr. Martell will assume the duties of Board Chairman currently held by Ted W. Love, MD, who will continue to act as lead independent director on the KaloBios Board. Mr. Martell has more than 25 years' experience building and managing unique businesses in the biotech industry, and most recently served as Chief Executive Officer at Sevion Therapeutics, prior to which he held similar roles at NeurogesX and at Poniard Pharmaceuticals.

Kalobios Pharmaceuticals, Inc. Proposes Series of Alternate Amendments to its Amended and Restated Certificate of Incorporation

KaloBios Pharmaceuticals, Inc. proposed a series of alternate amendments to its amended and restated certificate of incorporation, to effect, at the discretion of the board of directors, a reverse stock split of the company's common stock, whereby each outstanding 4, 5, 6, 7, 8, 9 or 10 shares would be combined, converted and changed into one share of common stock, at its annual general meeting will be held on July 7, 2015.

KaloBios Pharmaceuticals, Inc., Annual General Meeting, Jul 07, 2015

KaloBios Pharmaceuticals, Inc., Annual General Meeting, Jul 07, 2015., at 10:00 Pacific Standard Time. Location: the offices of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, 1200 Seaport Blvd. Agenda: To elect the seven nominees to the board of directors to hold office until the 2016 annual meeting of stockholders; to approve a series of alternate amendments to its amended and restated certificate of incorporation, to effect, at the discretion of the board of directors, a reverse stock split of the company's common stock, whereby each outstanding 4, 5, 6, 7, 8, 9 or 10 shares would be combined, converted and changed into one share of common stock; to approve amendments to its 2012 equity incentive plan to, among other things, increase the number of shares reserved for issuance there under by 2,500,000 shares on a pre-reverse stock split basis; to ratify the appointment of Ernst & Young LLP as its independent registered public accounting firm for the year ending December 31, 2015; and to transact any other business that may properly come before the meeting.

Similar Private Companies By Industry

Company Name Region
NexImmune, Inc. United States
Recombinetics, Inc. United States
Vesuvius Pharmaceuticals, Inc. United States
MultiVir, Inc. United States
Diogenics United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KaloBios Pharmaceuticals, Inc., please visit www.kalobios.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.